epidermal growth factor receptor trang 6 tải miễn phí từ TAILIEUCHUNG

"epidermal growth factor receptor" trang 6 - tải miễn phí từ Tailieuchung

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

17 72 0

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

9 82 0

Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

19 78 0

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

9 75 1

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: A multicenter observational study

11 32 0

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis

4 29 0

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

10 37 1

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

6 48 1

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

10 42 1

Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series

Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series

9 65 1

EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma

EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma

9 45 1

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand

12 62 1

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

6 43 1

Effect of neoadjuvant therapy on breast cancer biomarker profile

9 38 1

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

7 59 1

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

7 71 1

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis

7 40 1

Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study

Erlotinib treatment after platinum-based therapy in elderly patients with non-smallcell lung cancer in routine clinical practice – results from the ElderTac study

11 35 1

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

7 28 1

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial

7 59 1

Đầu
1
2
3
4
5
[ 6 ]
7
8
9
10
11
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.